Stock Price Quote

AARTI DRUGS LTD.

NSE : AARTIDRUGSBSE : 524348ISIN CODE : INE767A01016Industry : Pharmaceuticals & DrugsHouse : Aarti
BSE371.90-2.7 (-0.72 %)
PREV CLOSE ( ) 374.60
OPEN PRICE ( ) 375.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4167
TODAY'S LOW / HIGH ( )370.05 379.50
52 WK LOW / HIGH ( )318.6 574.95
NSE371.30-4.1 (-1.09 %)
PREV CLOSE( ) 375.40
OPEN PRICE ( ) 377.55
BID PRICE (QTY) 371.30 (1)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 146991
TODAY'S LOW / HIGH( ) 370.00 380.85
52 WK LOW / HIGH ( )318.95 564.05
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-09 1984
Management Info
Prakash M Patil - Chairman Rashesh C Gogri - Managing Director
Registered Office

Address Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka Palghar,
Thane,
Maharashtra-401506

Phone 022-24019025

Email investorrelations@aartidrugs.com

Website www.aartidrugs.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

18May Aarti Drugs informs about newspaper p
In accordance with Regulation 47 of SEBI (Listing Obligations and Disclo..
09Apr Aarti Drugs informs about newspaper pu
Aarti Drugs has enclosed herewith copies of the newspaper publication re..
07Mar Aarti Drugs gets nod to make investmen
Aarti Drugs has received approval to make investment in equity shares of..
07Mar Aarti Drugs informs about investment i
Aarti Drugs has informed that the Finance & Investment Committee at..
04Mar Aarti Drugs’ arm incorporates overseas
Aarti Drugs’ subsidiary -- Pinnacle Chile SpA, has incorporated an overs..
MORE

Financials

in Millions
QTR Mar 26 ANNUAL 26
Net Profit449.61692.2
Gross Profit 585.6 1813.1
Operating Profit 8012633.3
Net Sales 6316.822603.9
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  2532.75 (9.42%)
M.Cap ( in Cr)1396.23
Divi's Lab (BSE)
peergroup  6713.35 (1.59%)
M.Cap ( in Cr)178218.35
Orchid Pharma (BSE)
peergroup  1044.30 (8.71%)
M.Cap ( in Cr)5296.60
Glaxosmithkline Phar (BSE)
peergroup  2201.15 (3.60%)
M.Cap ( in Cr)37288.81
Astrazeneca Pharma I (BSE)
peergroup  8499.70 (0.88%)
M.Cap ( in Cr)21249.25
MORE

Shareholding Pattern

PROMOTERS 55.03%
NON-INSTITUTION 33.18%
MUTUAL FUNDS/UTI 10.14%
FI/BANKS/INSURANCE 0.08%
GOVERNMENT 0%
FII 0%
MORE

About Aarti Drugs Ltd.

Aarti Drugs Ltd. was incorporated in the year 1984. Its today's share price is 371.9. Its current market capitalisation stands at Rs 3394.33 Cr. In the latest quarter, company has reported Gross Sales of Rs. 21736.55 Cr and Total Income of Rs.21872.26 Cr. The company's management includes Narendra J Salvi, Ajit Eledath Venugopalan, Sandeep M Joshi, Hasmukh Dedhia, Neha R Gada, Bhaskar Narayan Thorat, Ankit Paleja, Uday M Patil, Harit P Shah, Harshit M Savla, Rashesh C Gogri, Prakash M Patil, Prakash M Patil, Chandrakant V Gogri, Rushikesh Deole.

It is listed on the BSE with a BSE Code of 524348 , NSE with an NSE Symbol of AARTIDRUGS and ISIN of INE767A01016. It's Registered office is at Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka PalgharThane-401506, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are GBCA & Associates, Gokhale & Sathe, Kirtane & Pandit LLP, Parikh Joshi & Kothare

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter NB PMS Insights SCORES complaints – May 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Contact Us
Mutual Funds About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update IRRA
Other Links Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI Scores RMS Policy Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025 FY-2025-2026 FY-2026-2027
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID MTF Terms
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AMLNBSPL Policy of SurveillanceNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.